Adhesive interactions regulate transcriptional diversity in malignant B cells

Molecular Cancer Research

Volumn 8, Issue 4, 2010, Pages 482-493

  Nadav Dagan, Liat ^a,b   Shay, Tal ^a   Dezorella, Nili ^b   Naparstek, Elizabeth ^b,c   Domany, Eytan ^a   Katz, Ben Zion ^b,c   Geiger, Benjamin ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; B LYMPHOCYTE; BIOINFORMATICS; CANCER CELL; CELL ADHESION; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTO ONCOGENE; TRANSCRIPTION REGULATION;

EID: 77951174428     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0182     Document Type: Article

References (45)

1. Bartos JD, Stoler DL, Matsui S, et al. Genomic heterogeneity and instability in colorectal cancer: spectral karyotyping, glutathione transferase-Ml and ras. Mutat Res 2004;568:283-292
2. Salvatore G, Nappi TC, Salerno P, et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 2007;67:10148-10158
3. Grushko TA, Dignam JJ, Das S, et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 2004;10:499-507.
4. Mottok A, Hansmann ML, Brauninger A. Activation induced cytidine deaminase expression in lymphocyte predominant Hodgkin lymphoma. J Clin Pathol 2005;58:1002-1004
5. Montesinos-Rongen M, Schmitz R, Courts C, et al. Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. Am J Pathol 2005;166:1773-1779
6. Smit LA, Bende RJ, Aten J, et al. Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype. Cancer Res 2003;63:3894-3898
7. Mattioli M, Agnelli L, Fabris S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005; 24:2461-2473
8. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-6338
9. Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 2003;194:96-104.
10. Hurt EM, Wiestner A, Rosenwald A, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004;5:191-199
11. De Vos J, Hose D, Reme T, et al. Microarray-based understanding of normal and malignant plasma cells. Immunol Rev 2006; 210:86-104.
12. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells. Oncogene 2003;22: 2417-2421
13. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323
14. Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009;113:149-153
15. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767
16. Shain KH, Yarde DN, Meads MB, et al. β1 Integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009;69:1009-1015
17. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res 2006;66:11089-11093
18. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-827
19. Nadav L, Katz BZ, Baron S, Cohen N, Naparstek E, Geiger B. The generation and regulation of functional diversity of malignant plasma cells. Cancer Res 2006;66:8608-8616
20. Nadav L, Kalchenko V, Barak MM, Naparstek E, Geiger B, Katz BZ. Tumorigenic potential and disease manifestations of malignant B-cell variants differing in their fibronectin adhesiveness. Exp Hematol 2008;36:1524-1534
21. Gooding RP, Bybee A, Cooke F, et al. Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia. Br J Haematol 1999;106:669-681
22. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125:279-284
23. Matys V, Fricke E, Geffers R, et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 2003;31:374-378
24. Tsafrir D, Tsafrir I, Ein-Dor L, Zuk O, Notterman DA, Domany E. Sorting points into neighborhoods (SPIN): data analysis and visualization by ordering distance matrices. Bioinformatics 2005;21:2301-2308
25. De Vos J, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001;98:771-780
26. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 2002;160:1293-1299
27. Guedez L, Martinez A, Zhao S, et al. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/ plasmablastic tumors. Blood 2005;105:1660-1668
28. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005;6:1054-1060
29. Ishikawa H, Tsuyama N, Abroun S, et al. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation. Leuk Lymphoma 2003;44: 1477-1481
30. Shapiro-Shelef M, Calame K. Plasma cell differentiation and multiple myeloma. Curr Opin Immunol 2004;16:226-234
31. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 1997; 276:596-599
32. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol 2001;2:1103-1108
33. Chen-Bettecken U, Wecker E, Schimpl A. Transcriptional control of μ- and κ-gene expression in resting and bacterial lipopolysaccharide- activated normal B cells. Immunobiology 1987;174:162-176
34. Hideshima T, Richardson P, Anderson KC. Novel therapeutic approaches for multiple myeloma. Immunol Rev 2003;194: 164-176
35. Mahtouk K, Jourdan M, De Vos J, et al. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 2004;103:1829-1837
36. Derksen PW, Tjin E, Meijer HP, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A 2004;101:6122-6127
37. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104: 607-618
38. Pope B, Brown R, Luo XF, Gibson J, Joshua D. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype. Leuk Lymphoma 1997;25:545-554
39. Xiao W, Hodge DR, Wang L, Yang X, Zhang X, Farrar WL. NF-κB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NFκB regulatory site in autocrine human multiple myeloma cells. Cancer Biol Ther 2004; 3:1007-1017
40. Feinman R, Siegel DS, Berenson J. Regulation of NF-κB in multiple myeloma: therapeutic implications. Clin Adv Hematol Oncol 2004;2: 162-166
41. Chai J, Tarnawski AS. Serum response factor: discovery, biochemistry, biological roles and implications for tissue injury healing. J Physiol Pharmacol 2002;53:147-157
42. Selvaraj A, Prywes R. Expression profiling of serum inducible genes identifies a subset of SRF target genes that are MKL dependent. BMC Mol Biol 2004;5:13.
43. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J, Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 2003; 101:1128-1140
44. Dezorella N, Pevsner-Fischer M, Deutsch V, et al. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6. Exp Cell Res 2009;315:1904-1913
45. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006;42:1564-1573